Excitotoxicity Peptides in Canada: A Research Guide to Glutamate Stress, Mitochondria, Semax, Selank, and RUO Controls

Why excitotoxicity deserves its own cognitive peptide guide#

Northern Compound already covers adjacent cognitive topics: neuroinflammation peptides, synaptic plasticity peptides, hippocampal neurogenesis peptides, blood-brain barrier peptide research, neurovascular coupling peptides, myelin repair peptides, sleep architecture peptides, and compound-level guides for Semax, Selank, and SS-31. What was still missing was an excitotoxicity-first article: how should Canadian readers evaluate peptide claims when the language is glutamate stress, calcium overload, neuronal survival, oxidative injury, or neuroprotection?

That gap matters because excitotoxicity is one of the most over-used words in cognitive and neuroprotection marketing. A paper may expose cultured neurons to glutamate and measure survival. A rodent model may involve ischemia-like stress, seizure-like activity, traumatic injury, or inflammatory priming. A supplier page may describe "neuroprotection" without specifying whether the peptide altered glutamate release, receptor signalling, mitochondrial function, antioxidant capacity, inflammation, or delayed cell death. Those are different claims with different endpoint requirements.

Excitotoxicity describes a cascade in which excessive excitatory signalling, often through glutamate receptors, drives calcium dysregulation and downstream stress. The mechanism intersects with mitochondria, reactive oxygen species, nitric oxide, energy failure, protease activation, membrane damage, inflammatory signalling, and synaptic loss. It is not a stand-alone proof that a material helps cognition. It is also not a licence to import human disease claims into a research-use-only product page.

This guide is written for Canadian readers evaluating non-clinical research-use-only peptide materials, supplier documentation, and evidence claims. It does not provide medical advice, disease treatment guidance, dosing, route selection, compounding instructions, or recommendations for personal use. Disease terms appear only to describe experimental models or the published literature.

The short answer: map the cascade before picking a peptide#

A defensible excitotoxicity project starts by naming the layer under test. "Protects neurons" is too broad. "Reduces glutamate toxicity" is still incomplete unless the protocol explains the insult, timing, cell type, matrix, and endpoint panel.

For the current Northern Compound product map, Semax is the strongest live product reference when a model centres on neurotrophin signalling, oxidative stress, ischemia-like injury, plasticity, or stress adaptation. Selank is coherent when GABA/glutamate balance, stress physiology, anxiety-like behaviour, or neuroimmune tone may shape the readout. SS-31 and MOTS-c are mitochondrial and metabolic-stress comparators. DSIP belongs only when sleep, recovery state, or circadian disruption is part of the excitotoxicity model rather than an implied benefit.

The endpoint chooses the peptide. A product link is a documentation starting point for an RUO material, not evidence that a material prevents neurological disease or improves human cognition.

Excitotoxicity biology in one cautious map#

Glutamate is the main excitatory neurotransmitter in the mammalian central nervous system. Normal synaptic glutamate signalling supports learning, plasticity, sensory processing, motor control, and network function. Excitotoxicity begins when excitatory signalling becomes excessive or poorly cleared relative to the energy and buffering capacity of the cell. The same molecule can therefore be essential in one context and damaging in another.

The classic cascade involves overactivation of ionotropic glutamate receptors, especially NMDA receptors and calcium-permeable AMPA receptors. Increased intracellular calcium can activate calpains, phospholipases, nitric oxide synthase, endonucleases, and mitochondrial stress pathways. Mitochondria attempt to buffer calcium and maintain ATP, but severe or sustained stress can collapse membrane potential, increase reactive oxygen species, impair respiration, and trigger delayed cell-death pathways. Reviews of excitotoxic injury emphasize this receptor-calcium-mitochondria sequence while warning that the details vary by model, developmental stage, and cell population (PMID: 28483900).

Astrocytes and microglia are not background scenery. Astrocytes regulate extracellular glutamate through transporters such as EAAT1 and EAAT2, maintain metabolic support, and shape the extracellular environment. Microglia can amplify or resolve injury depending on timing and stimulus. A peptide that appears neuroprotective in neuron-only culture may behave differently in organotypic slices, co-culture, or in vivo tissue where glia, blood flow, immune signalling, and metabolic substrates are present.

Energy state is central. Excitotoxicity is more severe when ATP is limited because ion gradients, glutamate uptake, calcium extrusion, vesicular cycling, and mitochondrial quality control all require energy. That is why ischemia-like oxygen-glucose deprivation, seizure-like depolarisation, and traumatic injury models often overlap with excitotoxic language. It also explains why mitochondrial peptides are relevant as comparators even when they do not directly bind glutamate receptors.

A careful article or protocol says: "In a primary cortical neuron-astrocyte co-culture exposed to defined glutamate concentration for a defined interval, the material preserved mitochondrial membrane potential, reduced calcium-overload markers, retained synaptic proteins, and improved survival after washout." A weak claim says: "The peptide blocks excitotoxicity."

Semax: neurotrophin and stress-response logic, not a blanket neuroprotection claim#

Semax is often discussed in cognitive peptide research because it sits near neurotrophin signalling, stress adaptation, plasticity, and injury-model literature. It is a heptapeptide related to an ACTH fragment, but its research framing should not be reduced to a generic stimulant or nootropic label. In an excitotoxicity-first article, the relevant question is whether a model has endpoints that connect Semax to survival, plasticity, oxidative stress, or neurotrophin response under a defined glutamate or ischemia-like challenge.

The stronger Semax research claims tend to involve brain injury, ischemia-related models, gene-expression changes, neurotrophic factors, antioxidant enzymes, inflammatory mediators, or behavioural outcomes after a defined insult. Those themes are adjacent to excitotoxicity because ischemia and energy failure can increase glutamate stress. They do not prove that Semax directly blocks NMDA receptors or prevents calcium influx. A rigorous Canadian editorial interpretation should therefore avoid phrases such as "anti-excitotoxic peptide" unless the underlying experiment actually measured glutamate receptor or calcium endpoints.

A Semax excitotoxicity model should ask several questions. Was the peptide present before, during, or after the insult? Was the insult glutamate itself, NMDA, kainate, oxygen-glucose deprivation, inflammatory priming, mechanical injury, or a seizure-like protocol? Were endpoints collected immediately, after recovery, or days later? Did the study measure BDNF, NGF, TrkB, CREB, antioxidant enzymes, mitochondrial respiration, or synaptic proteins? Did it include locomotor, arousal, or stress controls if behaviour was measured?

For sourcing, the same caution applies as in the intranasal cognitive peptides guide: a route-associated research tradition does not remove the need for identity, purity, storage, and stability documentation. Lot-specific HPLC and mass confirmation are more important than marketing adjectives. A current Semax product page can help locate an RUO material, but it is not a substitute for batch-level review.

Selank: stress, GABA/glutamate balance, and confounder control#

Selank is relevant to excitotoxicity only when the study design makes stress physiology, inhibitory-excitatory balance, or neuroimmune tone part of the hypothesis. Selank is commonly discussed around anxiolytic-like, stress-response, and immune-modulating research. Those themes can influence excitotoxicity endpoints because stress hormones, sleep disruption, inflammatory mediators, and inhibitory tone can all alter neuronal vulnerability.

The risk is overextension. A Selank study that changes anxiety-like behaviour does not automatically show reduced glutamate toxicity. A study that alters GABAergic or monoaminergic markers does not prove mitochondrial protection. A study that changes cytokine profiles does not prove synaptic preservation. The responsible frame is narrower: Selank may be a useful comparator when a model asks whether stress-state variables shift susceptibility to excitatory injury.

Useful endpoints include GABA/glutamate ratio, extracellular glutamate, receptor subunit expression, HPA-axis markers, corticosterone, inflammatory cytokines, microglial state, behavioural arousal, and sleep-state controls. In slice or cell models, researchers should decide whether Selank is being evaluated as a direct neuronal protectant, a glial-modulating material, or a stress-context variable. Those are not interchangeable.

For Canadian readers, the practical supplier question is documentation. Does the product page clearly identify Selank as research-use-only? Is there a current batch number, HPLC purity, mass confirmation, and realistic storage guidance? Are claims written as research context rather than personal anti-anxiety or neuroprotection promises? If not, the evidence interpretation should become more conservative, not more enthusiastic.

SS-31 and MOTS-c: mitochondrial comparators near excitotoxicity#

Excitotoxicity can be initiated by glutamate receptor overactivation, but much of the downstream injury is mitochondrial. Calcium overload, oxidative stress, impaired electron transport, cardiolipin disruption, ATP depletion, and cytochrome-c release can shape whether a cell recovers or dies. That is where SS-31 and MOTS-c become relevant as mitochondrial and metabolic-stress tools.

SS-31, also known as elamipretide in drug-development literature, is commonly framed around mitochondrial inner-membrane function, cardiolipin interactions, oxidative stress, and bioenergetics. Reviews of mitochondria-targeted peptide work discuss SS-31 in the context of membrane potential, ROS, and tissue injury models (PMID: 20618487; PMID: 35254804). In an excitotoxicity protocol, that makes SS-31 a mitochondria-focused comparator, not proof that glutamate signalling itself has been normalised.

MOTS-c is a mitochondrial-derived peptide studied across metabolic stress, AMPK-linked signalling, and mitonuclear communication. It is less direct for acute glutamate toxicity than SS-31, but it can be relevant when the model asks how energy state, insulin-like signalling, substrate availability, or cellular stress response changes vulnerability to excitatory injury. The endpoint panel should include respiration, ATP, AMPK, redox markers, glucose/lactate context, and survival after the insult.

The distinction matters for editorial accuracy. If a study shows that a mitochondrial peptide preserves ATP after glutamate exposure, the right claim is "bioenergetic resilience in an excitotoxicity model." It is not "blocks glutamate" unless receptor, transporter, or extracellular glutamate data support that mechanism. Northern Compound's mitochondrial peptides guide and oxidative stress peptides guide are better companion reads when the central endpoint is mitochondrial rather than synaptic.

DSIP and sleep-state excitability: relevant only when measured#

DSIP can appear in cognitive discussions because sleep, stress, and recovery state alter neuronal excitability. Sleep deprivation can change glutamate homeostasis, oxidative stress, inflammatory tone, seizure threshold, glymphatic function, and behavioural performance. Those variables can influence excitotoxicity models, especially in whole-animal research. But DSIP should not be presented as a direct anti-excitotoxic peptide unless the experiment actually tests that question.

A responsible DSIP frame is conditional. If a protocol examines whether disrupted sleep architecture increases susceptibility to excitatory injury, or whether recovery-state variables change glutamate-stress endpoints, then DSIP may be a relevant research material. If the protocol is a simple glutamate challenge in cell culture with no sleep or circadian component, DSIP is usually a weak fit.

Endpoint discipline is important. Sleep-state research should measure sleep architecture, circadian timing, locomotor activity, stress markers, and temperature context before interpreting neuroprotection. Otherwise, a behavioural change can be misread as synaptic rescue. The sleep architecture peptide guide is the better primary resource when sleep is the main mechanism and excitotoxicity is only a downstream concern.

Model selection: cell culture, slices, organoids, and in vivo injury models#

Excitotoxicity evidence changes meaning with the model. Primary neuron culture can isolate direct neuronal vulnerability, but it often lacks mature glial regulation, vascular context, immune complexity, and realistic extracellular buffering. Neuron-astrocyte co-culture improves glutamate-clearance relevance. Organotypic slices preserve more circuit architecture but add diffusion and viability constraints. Brain organoids can support development and cell-interaction questions, but maturity, vascular absence, and batch variability require caution.

In vivo models add blood flow, systemic stress, immune signalling, sleep state, temperature, metabolism, and behaviour. They also add confounders. A peptide may appear protective because it changes blood pressure, body temperature, locomotion, stress response, appetite, sleep, inflammation, or anaesthesia sensitivity rather than neuronal resistance to glutamate. That does not invalidate the finding, but it changes the interpretation.

Common excitotoxicity-adjacent models include direct glutamate exposure, NMDA exposure, kainate exposure, oxygen-glucose deprivation, middle cerebral artery occlusion models, traumatic brain injury models, seizure models, and inflammatory priming. Each has a different balance of receptor activation, energy failure, glial response, vascular injury, and delayed degeneration. Reviews of glutamate-mediated injury and receptor biology emphasize that timing and model architecture shape interpretation (PMID: 19808653).

A strong protocol pre-specifies the insult, exposure duration, peptide timing, recovery window, endpoints, exclusion criteria, and statistical plan. It also distinguishes prevention from rescue. Pre-treatment, co-treatment, and post-insult treatment answer different questions. A supplier article that collapses all three into "neuroprotective" is not precise enough.

Endpoint panel for a credible excitotoxicity study#

A minimal endpoint panel should not rely on one survival assay. MTT, resazurin, LDH release, and live/dead staining are useful screens, but each can be confounded by mitochondrial metabolism, membrane integrity, cell density, and timing. Excitotoxicity claims should triangulate survival, mechanism, and function.

The best studies include positive and negative controls. A known NMDA receptor antagonist may validate the model, even if it is not a relevant product. A mitochondrial stress control can show whether the assay detects bioenergetic rescue. Vehicle controls are mandatory. Peptide degradation controls are useful when the matrix contains serum, proteases, or long incubations.

Time-course design matters. Excitotoxicity can include an immediate calcium phase, an early mitochondrial phase, and delayed apoptosis or necrosis. A peptide that reduces calcium at five minutes may not improve survival at twenty-four hours. A peptide that preserves ATP at one hour may not retain synaptic markers later. Conversely, a peptide may fail to affect the initial calcium spike but improve recovery by altering mitochondrial or inflammatory state. The claim should follow the time point.

Supplier and COA review for Canadian RUO buyers#

For Canadian readers, supplier review should be boring in the best way. The label should say research-use-only. The product name, vial amount, batch number, and storage requirements should match the certificate of analysis. The COA should include HPLC purity and mass confirmation; ideally it should be lot-specific rather than a generic example. The supplier should avoid therapeutic promises and should not imply personal neurological use.

Excitotoxicity models are sensitive to impurities. Endotoxin, salts, residual solvents, wrong counterions, degradation products, pH changes, freeze-thaw damage, and concentration errors can alter cell stress. In neuron and glia models, inflammatory contamination can masquerade as a biological effect. In mitochondrial assays, vehicle or buffer mismatch can create false signals. The more subtle the claimed neuroprotection, the more important documentation becomes.

Storage and handling should be recorded without turning the article into a how-to-use guide. Researchers should document arrival condition, storage temperature, reconstitution matrix if applicable, aliquot plan, freeze-thaw exposure, light exposure, and assay timing. For peptides discussed here, the concern is not just whether the vial was pure on the manufacturing date; it is whether the material used in the experiment still matched the intended identity and concentration.

Product pages for Semax, Selank, SS-31, MOTS-c, and DSIP are best treated as starting points for documentation review. They are not medical recommendations. They are not proof of mechanism. They are not substitutes for batch-level COA verification.

How to read excitotoxicity claims without overstating them#

A practical editorial review can use five questions.

First, what was the insult? Glutamate, NMDA, kainate, oxygen-glucose deprivation, inflammatory priming, traumatic injury, seizure-like activity, and age-related vulnerability are not interchangeable. Each model includes a different mixture of receptor activation, energy failure, glial response, and delayed degeneration.

Second, what did the peptide change? Lower extracellular glutamate suggests exposure or clearance effects. Lower calcium suggests early signalling effects. Preserved ATP suggests bioenergetic resilience. Lower cytokines suggest inflammatory modulation. Better behavioural performance could reflect many mechanisms unless supported by tissue endpoints.

Third, when was the peptide present? Pre-treatment can test conditioning or vulnerability. Co-treatment can test acute interaction with the insult. Post-treatment can test recovery or delayed injury. A claim that ignores timing is usually too broad.

Fourth, did the study measure function? Cell survival is not the same as synaptic function. Behaviour is not the same as synaptic function either unless locomotion, anxiety-like behaviour, arousal, sleep, and motivation are controlled. Electrophysiology, synaptic proteins, dendritic morphology, and task design can help bridge the gap.

Fifth, was the material verified? The best mechanism paper becomes weak sourcing evidence if the product being evaluated has no lot-specific identity confirmation. In a Canadian RUO context, editorial confidence should depend on both literature quality and supplier documentation.

Evidence snapshots and cautious reference points#

The excitotoxicity field is large, and this article is not a systematic review. The goal is to provide a reading framework for peptide-related claims.

Glutamate excitotoxicity reviews describe the central role of receptor overactivation, calcium dysregulation, oxidative stress, mitochondrial dysfunction, and delayed cell-death pathways (PMID: 28483900). These papers are useful for mechanism mapping, but they do not validate any specific RUO peptide lot.

Mitochondrial peptide literature around SS-31 is relevant because mitochondrial dysfunction is a major downstream node in excitotoxic injury. Reviews discuss SS-31/elamipretide in relation to mitochondrial membranes, oxidative stress, and tissue-injury models (PMID: 20618487; PMID: 35254804). The responsible interpretation is bioenergetic resilience, not automatic anti-glutamate action.

Semax and Selank literature should be read through model-specific endpoints. If a paper measures neurotrophins, stress markers, inflammation, or behaviour after an injury-like insult, it may support a neuroprotection-adjacent hypothesis. It still needs glutamate, calcium, mitochondrial, or synaptic endpoints before it can support an excitotoxicity-specific claim. Broader neuropeptide reviews are helpful context but should not replace endpoint-level scrutiny (PMID: 30496712).

For metabolic and mitochondrial-derived peptides, MOTS-c literature often sits closer to energy stress and AMPK-linked adaptation than to acute synaptic glutamate. That can still matter in excitotoxicity because energy reserve changes vulnerability. It simply changes the claim: metabolic-stress modulation near excitotoxicity rather than direct receptor protection.

Internal linking map for related Northern Compound research#

Readers evaluating excitotoxicity should usually move through several adjacent guides instead of relying on one product page:

• Start with neuroinflammation peptides when microglia, cytokines, or inflammatory priming shape vulnerability.
• Use synaptic plasticity peptides when the claim involves memory, LTP, dendritic spines, or synaptic proteins.
• Use hippocampal neurogenesis peptides when the endpoint is newborn-neuron survival or BDNF in the dentate gyrus rather than acute glutamate injury.
• Use neurovascular coupling peptides and blood-brain barrier peptide research when ischemia, perfusion, permeability, or endothelial stress are central.
• Use mitochondrial peptides and oxidative stress peptides when the main readout is respiration, ROS, ATP, or mitochondrial membrane potential.
• Use sleep architecture peptides only when sleep-state biology is measured, not merely invoked.

This map prevents category drift. A glutamate model is not automatically a cognition model, an anti-ageing model, a sleep model, or a mitochondrial model. It becomes those things only when the endpoint panel supports the connection.

Practical red flags in product and article claims#

Be cautious when an article or supplier page says a peptide "prevents excitotoxicity" without naming the model. Be more cautious when it jumps from cell culture to human cognitive outcomes. Be especially cautious when it uses disease language as if an RUO product has a therapeutic indication.

Other red flags include missing COAs, generic purity claims, no mass confirmation, no batch number, mismatched vial amount, unsupported route language, personal-use wording, and claims that collapse Semax, Selank, SS-31, MOTS-c, and DSIP into one broad "brain peptide" category. These materials belong to different hypotheses.

A better claim is narrow: "This RUO material may be relevant to non-clinical models where neurotrophin response, stress physiology, mitochondrial resilience, or sleep-state variables are being measured alongside defined excitotoxic endpoints." That language is less exciting, but it is more accurate.

Receptor specificity: NMDA, AMPA, kainate, and metabotropic context#

Excitotoxicity is often shortened to "too much glutamate," but receptor specificity changes the biology. NMDA receptors are highly calcium-permeable under the right voltage and co-agonist conditions, making them central to many excitotoxicity models. AMPA receptors can also contribute, especially when subunit composition allows greater calcium permeability. Kainate receptors, metabotropic glutamate receptors, voltage-gated calcium channels, sodium loading, and impaired reuptake can all shape the cascade.

That receptor map matters for peptide articles because a material may influence one layer while leaving another untouched. A peptide that changes BDNF or CREB may alter survival pathways without changing receptor activation. A mitochondrial peptide may preserve ATP after receptor activation but not reduce the initial calcium load. A stress-modulating peptide may change behavioural vulnerability or endocrine tone without directly affecting synaptic receptor kinetics. Those are still useful research hypotheses, but they should not be collapsed into a single "glutamate blocker" claim.

Canadian readers should look for receptor and timing detail. Was the insult glutamate, NMDA, AMPA, kainate, quinolinic acid, oxygen-glucose deprivation, or another stressor? Was magnesium present? Was glycine or D-serine controlled? Was extracellular calcium defined? Were astrocytes present to clear glutamate? Was the endpoint immediate receptor activation, delayed cell death, or functional recovery? Without those details, an excitotoxicity claim is usually too vague to guide product selection.

Astrocytes, transporters, and metabolic support#

Astrocytes are central to glutamate homeostasis. They express excitatory amino acid transporters, convert glutamate to glutamine, regulate extracellular potassium, supply metabolic substrates, and influence antioxidant capacity. In many models, excitotoxicity worsens when astrocyte uptake is overwhelmed or energy availability is poor. That means a peptide can appear neuroprotective by supporting astrocyte function, changing inflammation, altering metabolism, or preserving mitochondrial state rather than by acting directly on neurons.

This distinction is especially important for mixed cultures, organotypic slices, and in vivo models. A neuron-only assay may miss transporter biology. A co-culture assay may show protection that depends on astrocyte condition. A whole-animal model may include vascular, immune, endocrine, and sleep-state effects. None of these are wrong; they simply answer different questions.

For a supplier-facing editorial review, the question is not "does this product page say neuroprotective?" The question is whether the proposed peptide matches the model architecture. Semax may be more coherent when neurotrophin response and injury adaptation are central. Selank may be more coherent when stress or inhibitory-excitatory tone is measured. SS-31 may be more coherent when mitochondrial resilience is the central endpoint. A credible protocol states that match explicitly.

Statistical and reporting standards for subtle neuroprotection claims#

Excitotoxicity assays can produce persuasive-looking results from fragile designs. Cell density, passage number, culture age, serum withdrawal, plating variability, oxygen tension, media composition, pH, osmolarity, and timing can all influence vulnerability. In slice and animal models, temperature, anaesthesia, handling stress, sex, age, strain, circadian timing, and injury severity can shift outcomes. A small survival difference is difficult to interpret if these variables are not controlled.

Strong reporting includes randomisation, blinded endpoint scoring where feasible, pre-specified exclusion criteria, power rationale, batch documentation, and separate biological replicates. It also reports negative results and toxicity screens. A peptide that is protective at one concentration but harmful at another should not be marketed as simply protective. A peptide that improves one marker while worsening another should be described as mixed, not as a success.

Endpoint hierarchy helps. Mechanistic markers such as calcium, ROS, and membrane potential explain early biology. Survival markers show whether the stress changed cell fate. Synaptic and electrophysiological endpoints show whether surviving cells retained relevant function. Behavioural endpoints can be useful in vivo, but only when confounders such as locomotion, arousal, anxiety-like behaviour, sleep, appetite, and sickness behaviour are measured. The more distant the endpoint is from glutamate receptor activation, the more controls are needed.

A Canadian RUO checklist for excitotoxicity-focused sourcing#

A practical sourcing review can be kept concise and repeatable:

1. Confirm the material name, sequence or identity description, vial amount, batch number, and research-use-only labelling.
2. Match the COA to the exact batch, not just the product category.
3. Look for HPLC purity and mass confirmation; consider endotoxin awareness for cell, slice, or immune-sensitive models.
4. Check storage guidance, shipping conditions, and whether the planned assay matrix could degrade the peptide.
5. Avoid suppliers that use therapeutic neurological claims, personal-use instructions, or disease-treatment language.
6. Record the lot, arrival date, storage log, preparation timing, and freeze-thaw history in the experiment file.
7. Keep product links and article citations separate: supplier documentation verifies material identity; literature evaluates biological plausibility.

This checklist is intentionally conservative. It protects the interpretation of subtle results. If a peptide appears to rescue a five-percent survival difference in a glutamate assay, a degraded or contaminated lot can erase the meaning of the experiment. If the material is clean and the endpoint panel is coherent, the discussion can still remain appropriately narrow.

Example interpretation scenarios#

Consider a neuron-astrocyte co-culture exposed to glutamate for thirty minutes, followed by washout and twenty-four-hour recovery. If Semax preserves synaptophysin and BDNF while only modestly changing early calcium, the most accurate claim is plasticity and recovery support in a glutamate-stress model. It is not evidence that Semax directly blocks glutamate receptors.

Consider an oxygen-glucose deprivation model where SS-31 preserves mitochondrial membrane potential and ATP but does not change extracellular glutamate. The accurate claim is mitochondrial resilience during excitotoxicity-adjacent energy stress. It should be cross-linked to mitochondrial and oxidative-stress research, not oversold as a broad cognitive enhancement finding.

Consider a whole-animal stress model where Selank changes anxiety-like behaviour and reduces inflammatory markers after an excitatory challenge. The responsible interpretation is stress-state or neuroimmune modulation unless receptor, calcium, mitochondrial, and synaptic endpoints confirm a narrower excitotoxicity mechanism. Behaviour alone is not enough.

Consider a sleep-deprivation protocol where DSIP changes sleep architecture and reduces vulnerability to a later glutamate-related insult. That can be an interesting recovery-state hypothesis, but it must report sleep metrics, circadian timing, locomotion, and stress markers. Otherwise, the effect could be arousal, temperature, or handling rather than excitotoxicity biology.

Bottom line for Canadian researchers#

Excitotoxicity is a valuable research lens because it forces precise questions about glutamate, calcium, mitochondria, synapses, glia, and delayed injury. It is also easy to misuse because the word sounds like a complete explanation. For Northern Compound readers, the safest approach is to map the mechanism, verify the material, and keep claims tied to endpoints.

Semax is the clearest live cognitive product reference when the model centres on neurotrophins, injury-like stress, plasticity, or oxidative context. Selank belongs when stress physiology, GABA/glutamate balance, or neuroimmune tone is part of the design. SS-31 and MOTS-c are mitochondrial and metabolic comparators. DSIP is conditional on sleep or recovery-state measurement.

None of those links are medical advice, treatment guidance, or personal-use recommendations. They are RUO documentation checkpoints. The evidence standard remains the same: defined insult, appropriate controls, endpoint triangulation, lot-specific COA review, and cautious language that does not turn non-clinical excitotoxicity data into human claims.